NAFLD, the liver is both victim and motor of a multisystem disease. Liver disease is not limited to the liver itself but has an impact on glycemic control in the body. Prof. Tacke discusses this vicious cycle and how NAFLD may add to coexisting risk factors and is predictor of morbidity and mortality. He shows why this is also important to develop new treatment strategies.
This retrospective study of Chinese patients (385) with NAFLD investigated changes in the level of serum 25-OH vitamin D [25-hydroxyvitamin D, 25(OH)D] in patients with non-alcoholic fatty liver disease (NAFLD) and the correlation between the severity of NAFLD and 25(OH)D. The analysis showed that they have lower 25-hydroxyvitamin circulating levels than controls. This confirms previous results.
Non-alcoholic fatty liver disease (NAFLD) is a risk factor for development of type 2 diabetes mellitus (T2DM). Based on long-term follow-ups, this work presents results suggesting that steatosis grade predicts mortality and the risk of developing T2DM in patients NAFLD.
In NAFLD/NASH clinical trials, liver biopsy is mandatory to assess eligibility and primary endpoints. It requires a lot of knowledge and skills to stage fibrosis and grade activity. Prof. Frank Bedossa discusses these important topics, as well as the different scores such as the NAFLD activity score (NAS) and the Steatosis Activity Fibrosis score (SAF).
Pooled results of the two randomized, double-blind, placebo-controlled, phase 3 trials testing selonsertib in NASH patients with bridging fibrosis and cirrhosis. Even if the results are negative important information on the natural history of the disease relevant for the design of future trials
This paper presents the results the cilofexor phase 2 randomized, placebo-controlled trial in patients with nonalcoholic steatohepatitis (NASH). This non-steroidal FXR agonist reduces significantly hepatic steatosis and shows target engagement with as expected pruritus as relevant side effect.
It is well known that NAFLD patients are at higher risk of cardiovascular events; but it is unknown whether the liver fibrosis index can predict AF risk. This work finds that fibrosis assessed by Fib-4 is associated with a higher risk to develop atrial fibrillation.
Notably, the primary cause of morbidity and mortality in patients with NAFLD is cardiovascular disease (CVD), with fibrosis stage being the strongest disease-specific predictor. This work reviews how NAFLD is closely associated with cardiovascular disease emphasizing the importance to screen accordingly NAFLD patients.
Prof. Frank Tacke discusses a paper in press in the Journal of Hepatology regarding the role of PPAR’s in experimental models and how these PPAR’s affect the progression of liver disease.
This meta-analysis shows that serum vitamin D levels are inversely associated with NAFLD, supporting that patients with low vitamin D patients might benefit from proper supplementation. Read More
This review articles summarizes the current evidence on the efficacy of dietary interventions in the treatment of NAFLD. Read More
Yann Colardelle / Med Ed GS
27 rue Raffet, 75016 Paris, France